检索范围:
排序: 展示方式:
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang, Linqi Zhang
《医学前沿(英文)》 2020年 第14卷 第1期 页码 30-42 doi: 10.1007/s11684-019-0721-9
关键词: HIV-1 broadly neutralizing antibodies Env conformational states vaccine design SOSIP
Human monoclonal antibodies as candidate therapeutics against emerging viruses
null
《医学前沿(英文)》 2017年 第11卷 第4期 页码 462-470 doi: 10.1007/s11684-017-0596-6
The emergence of new pathogens, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and Ebola virus, poses serious challenges to global public health and highlights the urgent need for novel antiviral approaches. Monoclonal antibodies (mAbs) have been successfully used to treat various diseases, particularly cancer and immunological disorders. Antigen-specific mAbs have been isolated using several different approaches, including hybridoma, transgenic mice, phage display, yeast display, and single B-cell isolation. Consequently, an increasing number of mAbs, which exhibit high potency against emerging viruses in vitro and in animal models of infection, have been developed. In this paper, we summarize historical trends and recent developments in mAb discovery, compare the advantages and disadvantages of various approaches to mAb production, and discuss the potential use of such strategies for the development of antivirals against emerging diseases. We also review the application of recently developed human mAbs against SARS-CoV, MERS-CoV, and Ebola virus and discuss prospects for the development of mAbs as therapeutic agents against emerging viral diseases.
关键词: human monoclonal antibodies emerging infectious diseases SARS-CoV MERS-CoV Ebola virus
Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying
《医学前沿(英文)》 2020年 第14卷 第2期 页码 149-159 doi: 10.1007/s11684-020-0764-y
关键词: influenza virus neutralizing antibody hemagglutinin globular head region trimeric interface
Synthesis of haptens and production of antibodies to bisphenol A
Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN
《农业科学与工程前沿(英文)》 2017年 第4卷 第3期 页码 366-372 doi: 10.15302/J-FASE-2017132
关键词: bisphenol A cross-reactivity hapten indirect competitive ELISA polyclonal antibody
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen
《医学前沿(英文)》 2020年 第14卷 第6期 页码 746-751 doi: 10.1007/s11684-020-0822-5
Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG
《农业科学与工程前沿(英文)》 2016年 第3卷 第2期 页码 153-160 doi: 10.15302/J-FASE-2016097
The biopharmaceutical industry in China: history and future perspectives
null
《医学前沿(英文)》 2012年 第6卷 第2期 页码 101-111 doi: 10.1007/s11684-012-0191-9
Biopharmaceuticals reflect the rapid progress achieved in modern biomedical research. This area has also become one of the main criteria for assessing the development level of biotechnology for a particular country. Although it has been only three decades since the first biopharmaceutical, recombinant human insulin, was licensed by the US Food and Drug Administration, the biopharmaceutical industry has become the fastest growing, most dynamic and technology-intensive sector in the biomedical field. Since the licensing of recombinant human interferon α1b in 1989, the biopharmaceutical industry in China has gone through initial developments and gradually entered a period of rapid growth. This paper provides an overview of the status and development trends of biopharmaceuticals in China, and compares them with those observed in developed countries.
关键词: biopharmaceuticals antibodies market trends diseases China national regulatory agency
Emerging immunological strategies: recent advances and future directions
《医学前沿(英文)》 2021年 第15卷 第6期 页码 805-828 doi: 10.1007/s11684-021-0886-x
关键词: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancer vaccines
null
《医学前沿(英文)》 2016年 第10卷 第1期 页码 76-84 doi: 10.1007/s11684-015-0426-7
Anti-β2 glycoprotein I (anti-β2GP I ) antibodies are important contributors to thrombosis, especially in patients with antiphospholipid syndrome (APS). However, the mechanism by which anti-β2GP I antibodies are involved in the pathogenesis of thrombosis is not fully understood. In this report, we investigated the role of anti-β2GP I antibodies in complexes with β2GP I as mediators of platelet activation, which can serve as a potential source contributing to thrombosis. We examined the involvement of the apolipoprotein E receptor 2' (apoER2') and glycoprotein I ba (GP I bα) in platelet activation induced by the anti-β2GP I /β2GP I complex. The interaction between the anti-β2GP I /β2GP I complex and platelets was examined using in vitro methods, in which the Fc portion of the antibody was immobilized using protein A coated onto a microtiter plate. Platelet activation was assessed by measuring GP II b/ III a activation and P-selectin expression and thromboxane B2 production as well as p38 mitogen-activated protein kinase phosphorylation. Our results revealed that the anti-β2GP I /β2GP I complex was able to activate platelets, and this activation was inhibited by either the anti-GP I bα antibody or the apoER2' inhibitor. Results showed that the anti-β2GP I /β2GP I complex induced platelet activation via GP I bα and apoER2', which may then contribute to the prothrombotic tendency in APS patients.
关键词: anti-β2GP I /β2GP I complex platelet GP I bα apoER2' thrombosis
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
《医学前沿(英文)》 2021年 第15卷 第4期 页码 644-648 doi: 10.1007/s11684-021-0847-4
关键词: neutralizing antibody antibody cocktail SARS-CoV-2 COVID-19 therapeutic strategy
Passive antibody therapy in emerging infectious diseases
《医学前沿(英文)》 doi: 10.1007/s11684-023-1021-y
关键词: SARS-CoV-2 COVID-19 convalescent plasma hyperimmunoglobulin neutralizing monoclonal antibodies
Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,
《工程(英文)》 doi: 10.1016/j.eng.2023.09.012
关键词: Poly- N -acetylglucosamine Conjugate vaccine Monoclonal antibody
《医学前沿(英文)》 2022年 第16卷 第1期 页码 139-149 doi: 10.1007/s11684-021-0835-8
关键词: B-cell acute lymphoblastic leukemia bispecific antibody trispecific antibody CD19 CD20
A comprehensive analysis of immunoglobulin heavy chain genes in the Bactrian camel (
Zuoxiang LIANG,Tao WANG,Yi SUN,Wenlong YANG,Zhihong LIU,Jing FEI,Ying GUO,Qingwei MA,Qingjie PAN,Liming REN
《农业科学与工程前沿(英文)》 2015年 第2卷 第3期 页码 249-259 doi: 10.15302/J-FASE-2015056
提升疗效的修饰型治疗性抗体国内外研究进展 Review
戴济民, 张雪芹, 戴竞耀, 杨向民, 陈志南
《工程(英文)》 2021年 第7卷 第11期 页码 1529-1540 doi: 10.1016/j.eng.2020.06.030
生物治疗药物市场的繁荣反映了治疗性抗体药物用于治疗癌症、炎性疾病和难治性感染的可行性和有效性。随着抗体药物临床试验和转化研究中出现的结合效率不高、效应功能降低和不良反应频发等问题的解决,治疗性抗体的修饰在抗体药物的研发进程中得到了前所未有的蓬勃发展。为了提升抗体的结合活性、循环中的半衰期、靶细胞的有效性,并最终实现改善抗体药物的疗效,抗体可主要通过以下途径修饰:①糖基化修饰;②抗体恒定区(Fc)改造;③抗体亚类重构;④构建抗体-药物偶联物(ADC);⑤基于单链可变区片段(scFv)的嵌合抗原受体T细胞(CAR-T);⑥双特异性抗体(bsAb)。过去几十年来全球在修饰型治疗性抗体的领域取得了许多成就,中国作为对于生物治疗药物需求巨大并且拥有巨大研发潜力的国家在该领域亦发挥了积极作用。本文概括了修饰型治疗性抗体在当前国际研究中取得的进展,并在单独的章节中重点介绍了中国在该领域取得的成果。
标题 作者 时间 类型 操作
Broadly neutralizing antibodies and vaccine design against HIV-1 infection
Qian Wang, Linqi Zhang
期刊论文
Recent advances in “universal” influenza virus antibodies: the rise of a hidden trimeric interface in
Yulu Wang, Dan Hu, Yanling Wu, Tianlei Ying
期刊论文
Synthesis of haptens and production of antibodies to bisphenol A
Xiya ZHANG, Xiaoyun DONG, Sijun ZHAO, Yuebin KE, Kai WEN, Suxia ZHANG, Zhanhui WANG, Jianzhong SHEN
期刊论文
Durability of neutralizing antibodies and T-cell response post SARS-CoV-2 infection
Yun Tan, Feng Liu, Xiaoguang Xu, Yun Ling, Weijin Huang, Mingquan Guo, Ziyu Fu, Dongguo Liang, Miao Xu, Hongzhou Lu, Saijuan Chen
期刊论文
Characterization of polyclonal antibodies against nonstructural protein 9 from the porcine reproductive
Mengmeng ZHAO,Juanjuan QIAN,Jiexiong XIE,Tiantian CUI,Songling FENG,Guoqiang WANG,Ruining WANG,Guihong ZHANG
期刊论文
Anti-β glycoprotein I antibodies in complex with β2 glycoprotein I induce platelet activation via two
null
期刊论文
Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections
Rongtao Lai, Tianhui Zhou, Xiaogang Xiang, Jie Lu, Haiguang Xin, Qing Xie
期刊论文
Antibodies Targeting a Conserved Surface Polysaccharide Are Protective Against a Wide Range of Microbial
Xi Lu,Guoqing Li,Jing Pang,Xinyi Yang,Colette Cywes-Bentley,Xuefu You,Gerald B. Pier,
期刊论文
Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies
期刊论文
A comprehensive analysis of immunoglobulin heavy chain genes in the Bactrian camel (
Zuoxiang LIANG,Tao WANG,Yi SUN,Wenlong YANG,Zhihong LIU,Jing FEI,Ying GUO,Qingwei MA,Qingjie PAN,Liming REN
期刊论文